Moderna’s coronavirus vaccine shows promising immune response

Moderna’s coronavirus vaccine shows promising immune response

On Tuesday, 14th July 2020, Moderna American Biotech Company announced that it will begin human trials on 27th July, which is the third phase of the experimental coronavirus vaccine, (https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19?utm_source=homepage&utm_medium=slider&utm_campaign=covid) (https://www.inventiva.co.in/trends/tamanna/covid-19-vaccine-us-based-moderna-companys-covid-19-vaccine-showed-effective-results-and-ready-to-enter-phase-3-trials-on-july-27/).

The above announcement followed the promising immune response against the virus that also appeared safe in the first 45 people who received it, according to researchers who reported in The New England Journal of Medicine (https://www.business-standard.com/article/current-affairs/moderna-s-coronavirus-vaccine-tested-in-humans-shows-early-promise-120071600298_1.html).

Over half of the participants in the study also reported side effects, including fatigue, chills, aches, and pain at the injection site, but generally, the vaccine was well-tolerated (https://www.bostonmagazine.com/news/2020/07/15/moderna-vaccine-trial/).

It should be noted that the expected Phase 3 test will assess how the vaccine can protect humans against the SARS-CoV-2 virus which causes COVID-19. It will test the vaccine on 30,000 adults, including people whose locations or circumstances make them high-risk candidates for infection. The study will be conducted at 87 locations across the US, and this will be the final trial stage before regulators determine whether to make the vaccine available.

It is important to point out that Moderna became the first company in the United States to declare an estimated start date for the Phase 3 trial (https://www.inventiva.co.in/trends/tamanna/covid-19-vaccine-us-based-moderna-companys-covid-19-vaccine-showed-effective-results-and-ready-to-enter-phase-3-trials-on-july-27/).

In a press release, Moderna stated that if all goes well in future studies, then “”the Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021″ (https://edition.cnn.com/2020/07/14/health/moderna-coronavirus-vaccine-phase-1-study/index.html).

As a result of the promising immune response, Moderna’s shares surged as much as 18% on Wednesday, 15th July 2020. According to one Wall Street firm, Moderna will surge another 60% on the value of its potential coronavirus vaccine (https://markets.businessinsider.com/news/stocks/moderna-stock-price-could-surge-potential-coronavirus-vaccine-target-raise-2020-7-1029398327#).

Other companies researching vaccines for the virus, including AstraZeneca, Pfizer Inc. and Merck & Co also saw their shares rose, and optimism over Moderna lifted global equity markets (https://www.financialexpress.com/lifestyle/health/moderna-fires-up-covid-vaccine-race-with-promising-early-results/2025588/).

However, it is important to note that scientists are questioning whether the waning immunity to Covid-19 could affect how useful a vaccine will be in tackling the pandemic, following a study from King’s College London, that showed that recovered patients’ antibodies declined significantly within months of infection (https://www.ft.com/content/2aec0597-1de3-4181-93a0-1da9483d8b26?accessToken=zwAAAXNWmhuYkc8q7AWXHeNBgdOToB2pSD2LJg.MEYCIQDxT1B_DnFkDCRoBmt4N65bFhihrBLFAoOzwvd_3tf9nQIhAMzsmpjqfNPXlFKHCdBowIPWlHx6rhAhyWFWC4D_GsF6&sharetype=gift?token=9d62c1ba-41c5-4c0e-8cfc-92b2801656e5).